NATIONALLY – Johnson
Johnson
“We will have to respect the privacy of this participant. We are also learning more about this participant’s illness, and it is vital to have all the facts before sharing more information,” the company said in a statement.
News of the trial disruption was first reported through the STAT fitness data site
Dr. Ashish Jha of Brown University said the rupture is not without delay a concern, and said it is the largest trial I have ever noticed with another 60,000 people and that ruptures were expected.
The company said it follows the rules “so that there can be a careful review of all medical data before deciding to restart the study. “
Temporary closures of giant medical studies are common; few are made public in typical drug trials, but paints to make a vaccine opposed to coronavirus have increased the risks of such complications.
Companies are required to investigate any serious or unforeseen reaction that occurs in drug tests, since these tests are performed on tens of thousands of people, some medical conditions are a coincidence, in fact, one of the first steps that the corporation has announced is to calculate whether the user has won the vaccine or a placebo.
The Johnson Vaccine
President Donald Trump has promised a coronavirus vaccine before the November election, but that may not be possible, with obstacles along the way in several trials.
Speaking on a virtual physical care occasion at Goldman Sachs last week, U. S. Secretary of Health and Human Services Alex Azar said he was running to make sure enough materials were manufactured.
“At the end of FDA approvals, we can also have up to one hundred million doses until the end of the year, enough to cover vulnerable populations. And we may have enough for each and every American who needs a vaccine from March to April. 2021, ” said Azar.
Last month, the AstraZeneca COVID-19 vaccine test was discontinued to determine whether receptor disease was a side effect of the injection.
Since then, the trial has resumed in part, end-stage tests are still suspended in the United States, while officials are examining whether a disease in their trial poses a risk of protection.
This trial stopped when a woman developed severe neurological symptoms compatible with transverse myelitis, a rare inflammation of the spinal cord, the company said.
Johnson
The Associated Press contributed to the report.